Carcinoma, Hepatocellular Clinical Trial
Official title:
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT). Remote ischemic conditioning will consist of 3 cycles of 5 minutes of lower limb ischemia induced via a mid-thigh pneumatic tourniquet, followed by 5 minutes of reperfusion. Interventions will take place after anesthesia induction but before surgery, at the completion of the procedure, and on the mornings of post-operative days 1-4.
Orthotopic liver transplantation (OLT) is associated with a very high risk of complications.
In a recent multi-center study of 450 patients, 79% had at least one complication and 63% had
severe (Clavien-Dindo grade III or higher) complications. The number and severity of
complications are associated with death within 30 days, hospital length of stay, graft and
patient survival. Infections are the most common group of complications, followed by
pulmonary, renal and liver graft dysfunction. Interventions that decrease these complications
after OLT are likely to improve clinical outcomes.
Remote ischemic conditioning is an innate biological phenomenon wherein a brief single or
repetitive ischemic stimulus in an organ or tissue such as skeletal muscle induce protection
in remote/distant organs against ischemia and other noxious stimuli. This effect can be
induced by inflating a pneumatic tourniquet on a leg or arm for a few minutes (usually 5-10)
and subsequently deflating to allow reperfusion. This process is usually repeated 3-4 times
to ensure an adequate dose of the conditioning stimulus. The conditioning stimulus could be
applied before (Preconditioning), concurrent with (Perconditioning), or soon after the index
noxious/ischemic insult (Postconditioning).
The goal of this study is to assess the feasibility, patient acceptance, and safety of RIC in
liver recipients. In addition, the investigators will obtain data on posttransplant
complications. Information obtained from this study will help guide the design of a future
randomized, controlled trial to test the benefit of RIC in liver recipients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03289533 -
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
|
Phase 1 | |
Terminated |
NCT01141478 -
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
|
N/A | |
Recruiting |
NCT05580835 -
PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
Active, not recruiting |
NCT05389527 -
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04560751 -
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
|
||
Withdrawn |
NCT02939807 -
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01915602 -
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
Recruiting |
NCT02403544 -
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT01897038 -
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Terminated |
NCT01337492 -
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|
Phase 0 | |
Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT01003015 -
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT00559455 -
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT00384800 -
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT00582400 -
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
|
Phase 2 | |
Completed |
NCT00056992 -
Testing of ADI-PEG in Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT02859324 -
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
|
Phase 1/Phase 2 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A |